Fibroblast Growth Factor Signaling in Lung Diseases: From Biological Roles to Therapeutic Delivery Strategies
International Journal of Stem Cells · 07.08.2026
DOI: 10.15283/ijsc26054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Stem Cells, online erschienen am 07.08.2026. Verfasst von Se Bi Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Kangwon National University Hospital, Kangwon National University, Chuncheon, Korea. Gefördert von: Ministry of Science and ICT, South Korea, Gangwon ANCHOR Center, Ministry of Education.
Abstract (Originalsprache)
As human longevity continues to increase globally, the prevalence of age-related deterioration and associated chronic lung diseases has risen in parallel. Unlike many organs, the lung is continuously exposed to environmental insults, leading to cumulative cellular damage, impaired epithelial progenitor activity, and chronic inflammation, which contribute to diseases such as pulmonary fibrosis and chronic obstructive pulmonary disease. Under physiological conditions, lung homeostasis is maintained by epithelial progenitor cells, particularly alveolar type II cells. However, this regenerative capacity is often disrupted in chronic lung diseases, resulting in impaired repair and fibrotic remodeling. Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in epithelial regeneration, cell survival, and tissue repair. Despite their therapeutic potential, clinical translation remains limited by poor protein stability, rapid proteolytic degradation, low delivery efficiency across biological barriers, and insufficient cell-type specificity due to broad FGFR expression. Recently, several delivery strategies have been evaluated in preclinical lung disease models, including protein engineering, nanoparticle and liposome-based platforms, protein transduction domain- and cell-penetrating peptide-based intracellular delivery, and mesenchymal stem cell-based approaches. Therefore, this review summarizes the roles of FGF signaling in lung regeneration and age-associated diseases, and discusses emerging delivery strategies aimed at bridging the gap between preclinical efficacy and clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Kangwon National University Hospital, Kangwon National University, Chuncheon, Korea.
- Biomedical Research Institute, Kangwon National University Hospital, Chuncheon, Korea.
- Department of Dermatology, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.
- Department of Marine Convergence Science, Kangwon National University, Gangneung, Korea.
ORCID-Profile: Se Bi Lee, Young Her, Dae-Hee Lee, Se-Ran Yang
Förderung
- Ministry of Science and ICT, South Korea
- Gangwon ANCHOR Center
- Ministry of Education
- Gangwon State, Republic of Korea
Zitieren
APA
Lee, S. B., Her, Y., Lee, D. H., & Yang, S. R. (2026). Fibroblast Growth Factor Signaling in Lung Diseases: From Biological Roles to Therapeutic Delivery Strategies. International Journal of Stem Cells. https://doi.org/10.15283/ijsc26054
Vancouver
Lee SB, Her Y, Lee DH, Yang SR. Fibroblast Growth Factor Signaling in Lung Diseases: From Biological Roles to Therapeutic Delivery Strategies. International Journal of Stem Cells. 2026. doi:10.15283/ijsc26054
BibTeX
@article{Lee2026,
author = {Lee, Se Bi and Her, Young and Lee, Dae-Hee and Yang, Se-Ran},
title = {Fibroblast Growth Factor Signaling in Lung Diseases: From Biological Roles to Therapeutic Delivery Strategies},
journal = {International Journal of Stem Cells},
year = {2026},
doi = {10.15283/ijsc26054}
}
EUVIMED